生物製剤受託製造の市場規模、シェア、動向分析レポート：製品別、適応症別、地域別、セグメント予測、2025年～2030年

生物製剤受託製造市場の成長と動向

Grand View Research, Inc.の最新レポートによると、世界の生物製剤受託製造市場規模は2025～2030年にかけてCAGR 10.3％を記録し、2030年には575億9,000万米ドルに達すると予測されています。

世界市場はCOVID-19の流行期に効率的に成長しました。これはCOVID-19ワクチン開発のための研究開発活動が活発化したためです。さらに、感染拡大を抑制するための製造施設の拡大もあった。例えば、2021年11月、ロンザ社は、同社の今後のプロジェクトをサポートするため、スイスの微生物開発ラボの拡大を決定したと発表しました。

パンデミック後には、数多くの根本的な変化が起こると考えられています。コロナウイルスに対するワクチンと治療の開発のための生産と製造の取り組みが増加し、すべての事業部門にわたってデジタル機能が高まると考えられます。これらの取り組みは、より戦略的なパートナーシップを構築する上で、製薬企業との共同計画に役立つと考えられます。例えば、2022年1月、ロンザは生物特異的な抗体の発見と設計に使用される技術を発表し、この技術はbYlok（TM）と呼ばれます。医薬品や生物製剤の製造アウトソーシングは世界中で急速に増加しています。

製薬会社やバイオテクノロジー企業は、医薬品や生物製剤の製造に関連する運営コストを削減する一方で、中核となるプロジェクトに集中しています。製造受託機関（CMO）は、製造の全プロセスを実施することに特化し、経験豊富です。生物製剤の自社製造は複雑なプロセスであり、多くのリソースを必要とするため困難です。CMOは、創薬プロセスの改善に注力することで、需要と供給のギャップを埋め、その結果、生物製剤をより早く患者に提供することができます。そのため、アウトソーシングは急速に増加しています。

生物製剤受託製造市場レポートハイライト

• 製品別では、がん、感染症、喘息、自己免疫疾患など幅広い疾患の治療にMABが使用されていることから、MABセグメントが2024年に最大の売上シェアを占めました。
• 適応症別では、がん領域が2024年に最大の収益シェアで市場を独占しました。このセグメントシェアが高い主要要因は、がん患者数の増加です。
• 北米は、医薬品・生物製剤製造のアウトソーシングサービスが増加しており、研究開発費も高いことから、2024年の世界市場を席巻しました。

目次

第1章 調査手法と範囲

第2章 エグゼクティブサマリー

第3章 バイオ医薬品受託製造市場の変数、動向、範囲

• 市場系統の展望
• 市場力学
  • 市場促進要因分析
  • 市場抑制要因分析
• ビジネス環境分析
  • 産業分析-ポーターのファイブフォース分析
  • PESTLE分析

第4章 バイオ医薬品受託製造市場：製品ビジネス分析

• 製品市場シェア、2024年と2030年
• 製品セグメントダッシュボード
• 市場規模と予測と動向分析、製品別、2018～2030年
• モノクローナル抗体（mAbs）
• 組み換えタンパク質
• ワクチン
• アンチセンス、RNAi、分子療法
• その他

第5章 バイオ医薬品受託製造市場： 適応症ビジネス分析

• 適応症市場シェア、2024年と2030年
• 適応症セグメントダッシュボード
• 市場規模と予測と動向分析、適応症別、2018～2030年
• 腫瘍学
• 自己免疫疾患
• 感染症
• 心血管疾患
• 代謝性疾患
• 神経学
• その他

第6章 バイオ医薬品受託製造市場：製品と適応症による地域別、推定・動向分析

• 地域別市場シェア分析、2024年と2030年
• 地域別市場ダッシュボード
• 市場規模と予測動向分析、2018～2030年
• 北米
  • 国別、2018～2030年
  • 米国
  • カナダ
  • メキシコ
• 欧州
  • 国別、2018～2030年
  • 英国
  • ドイツ
  • フランス
  • イタリア
  • スペイン
  • デンマーク
  • スウェーデン
  • ノルウェー
• アジア太平洋
  • 日本
  • 中国
  • インド
  • オーストラリア
  • タイ
  • 韓国
• ラテンアメリカ
  • 国別、2018～2030年
  • ブラジル
  • アルゼンチン
• 中東・アフリカ
  • 国別、2018～2030年
  • 南アフリカ
  • サウジアラビア
  • アラブ首長国連邦
  • クウェート

第7章 競合情勢

• 参加者概要
• 企業の市況分析
• 企業分類
• 戦略マッピング
• 企業プロファイル/上場企業
  • Wuxi Biologics.
  • FUJIFILM Diosynth BIoTechnologies.
  • Boehringer Ingelheim International GmbH
  • Lonza
  • Samsung Biologics
  • AbbVie Inc.
  • Catalent
  • Bioreliance（Merck KGaA）
  • Thermo Fisher Scientific Inc.
  • Eurofins Scientific

List of Tables

• Table 1 List of secondary sources
• Table 2 List of abbreviations
• Table 3 Global biologics contract manufacturing market, by region, 2018 - 2030 (USD Million)
• Table 4 Global biologics contract manufacturing market, by product, 2018 - 2030 (USD Million)
• Table 5 Global biologics contract manufacturing market, by indication, 2018 - 2030 (USD Million)
• Table 6 North America biologics contract manufacturing market, by country, 2018 - 2030 (USD Million)
• Table 7 North America biologics contract manufacturing market, by product, 2018 - 2030 (USD Million)
• Table 8 North America biologics contract manufacturing market, by indication, 2018 - 2030 (USD Million)
• Table 9 U.S. biologics contract manufacturing market, by product, 2018 - 2030 (USD Million)
• Table 10 U.S. biologics contract manufacturing market, by indication, 2018 - 2030 (USD Million)
• Table 11 Canada biologics contract manufacturing market, by product, 2018 - 2030 (USD Million)
• Table 12 Canada biologics contract manufacturing market, by indication, 2018 - 2030 (USD Million)
• Table 13 Mexico biologics contract manufacturing market, by product, 2018 - 2030 (USD Million)
• Table 14 Mexico biologics contract manufacturing market, by indication, 2018 - 2030 (USD Million)
• Table 15 Europe biologics contract manufacturing market, by country, 2018 - 2030 (USD Million)
• Table 16 Europe biologics contract manufacturing market, by product, 2018 - 2030 (USD Million)
• Table 17 Europe biologics contract manufacturing market, by indication, 2018 - 2030 (USD Million)
• Table 18 UK biologics contract manufacturing market, by product, 2018 - 2030 (USD Million)
• Table 19 UK biologics contract manufacturing market, by indication, 2018 - 2030 (USD Million)
• Table 20 Germany biologics contract manufacturing market, by product, 2018 - 2030 (USD Million)
• Table 21 Germany biologics contract manufacturing market, by indication, 2018 - 2030 (USD Million)
• Table 22 France biologics contract manufacturing market, by product, 2018 - 2030 (USD Million)
• Table 23 France biologics contract manufacturing market, by indication, 2018 - 2030 (USD Million)
• Table 24 Italy biologics contract manufacturing market, by product, 2018 - 2030 (USD Million)
• Table 25 Italy biologics contract manufacturing market, by indication, 2018 - 2030 (USD Million)
• Table 26 Spain biologics contract manufacturing market, by product, 2018 - 2030 (USD Million)
• Table 27 Spain biologics contract manufacturing market, by indication, 2018 - 2030 (USD Million)
• Table 28 Denmark biologics contract manufacturing market, by product, 2018 - 2030 (USD Million)
• Table 29 Denmark biologics contract manufacturing market, by indication, 2018 - 2030 (USD Million)
• Table 30 Sweden biologics contract manufacturing market, by product, 2018 - 2030 (USD Million)
• Table 31 Sweden biologics contract manufacturing market, by indication, 2018 - 2030 (USD Million)
• Table 32 Norway biologics contract manufacturing market, by product, 2018 - 2030 (USD Million)
• Table 33 Norway biologics contract manufacturing market, by indication, 2018 - 2030 (USD Million)
• Table 34 Asia Pacific biologics contract manufacturing market, by country, 2018 - 2030 (USD Million)
• Table 35 Asia Pacific biologics contract manufacturing market, by product, 2018 - 2030 (USD Million)
• Table 36 Asia Pacific biologics contract manufacturing market, by indication, 2018 - 2030 (USD Million)
• Table 37 Japan biologics contract manufacturing market, by product, 2018 - 2030 (USD Million)
• Table 38 Japan biologics contract manufacturing market, by indication, 2018 - 2030 (USD Million)
• Table 39 China biologics contract manufacturing market, by product, 2018 - 2030 (USD Million)
• Table 40 China biologics contract manufacturing market, by indication, 2018 - 2030 (USD Million)
• Table 41 India biologics contract manufacturing market, by product, 2018 - 2030 (USD Million)
• Table 42 India biologics contract manufacturing market, by indication, 2018 - 2030 (USD Million)
• Table 43 Australia biologics contract manufacturing market, by product, 2018 - 2030 (USD Million)
• Table 44 Australia biologics contract manufacturing market, by indication, 2018 - 2030 (USD Million)
• Table 45 Thailand biologics contract manufacturing market, by product, 2018 - 2030 (USD Million)
• Table 46 Thailand biologics contract manufacturing market, by indication, 2018 - 2030 (USD Million)
• Table 47 South Korea biologics contract manufacturing market, by product, 2018 - 2030 (USD Million)
• Table 48 South Korea biologics contract manufacturing market, by indication, 2018 - 2030 (USD Million)
• Table 49 Latin America biologics contract manufacturing market, by country, 2018 - 2030 (USD Million)
• Table 50 Latin America biologics contract manufacturing market, by product, 2018 - 2030 (USD Million)
• Table 51 Latin America biologics contract manufacturing market, by indication, 2018 - 2030 (USD Million)
• Table 52 Brazil biologics contract manufacturing market, by product, 2018 - 2030 (USD Million)
• Table 53 Brazil biologics contract manufacturing market, by indication, 2018 - 2030 (USD Million)
• Table 54 Argentina biologics contract manufacturing market, by product, 2018 - 2030 (USD Million)
• Table 55 Argentina biologics contract manufacturing market, by indication, 2018 - 2030 (USD Million)
• Table 56 Middle East & Africa Biologics contract manufacturing market, by country, 2018 - 2030 (USD Million)
• Table 57 Middle East & Africa biologics contract manufacturing market, by product, 2018 - 2030 (USD Million)
• Table 58 Middle East & Africa biologics contract manufacturing market, by indication, 2018 - 2030 (USD Million)
• Table 59 South Africa biologics contract manufacturing market, by product, 2018 - 2030 (USD Million)
• Table 60 South Africa biologics contract manufacturing market, by indication, 2018 - 2030 (USD Million)
• Table 61 Saudi Arabia biologics contract manufacturing market, by product, 2018 - 2030 (USD Million)
• Table 62 Saudi Arabia biologics contract manufacturing market, by indication, 2018 - 2030 (USD Million)
• Table 63 UAE biologics contract manufacturing market, by product, 2018 - 2030 (USD Million)
• Table 64 UAE biologics contract manufacturing market, by indication, 2018 - 2030 (USD Million)
• Table 65 Kuwait biologics contract manufacturing market, by product, 2018 - 2030 (USD Million)
• Table 66 Kuwait biologics contract manufacturing market, by indication, 2018 - 2030 (USD Million)

List of Figures

• Fig. 1 Biologics contract manufacturing market segmentation
• Fig. 2 Market research process
• Fig. 3 Data triangulation techniques
• Fig. 4 Primary research pattern
• Fig. 5 Market research approaches
• Fig. 6 Market formulation & validation
• Fig. 7 Market snapshot
• Fig. 8 Product and indication outlook (USD Million)
• Fig. 9 Competitive landscape
• Fig. 10 Biologics contract manufacturing market dynamics
• Fig. 11 Biologics contract manufacturing market: Porter's five forces analysis
• Fig. 12 Biologics contract manufacturing market: PESTLE analysis
• Fig. 13 Biologics contract manufacturing market: Product segment dashboard
• Fig. 14 Biologics contract manufacturing market: Product market share analysis, 2024 & 2030
• Fig. 15 Monoclonal Antibodies (mAbs) market, 2018 - 2030 (USD Million)
• Fig. 16 Recombinant proteins market, 2018 - 2030 (USD Million)
• Fig. 17 Vaccines market, 2018 - 2030 (USD Million)
• Fig. 18 Antisense, RNAi, & molecular therapy market, 2018 - 2030 (USD Million)
• Fig. 19 Others market, 2018 - 2030 (USD Million)
• Fig. 20 Biologics contract manufacturing market: Indication segment dashboard
• Fig. 21 Biologics contract manufacturing market: Indication market share analysis, 2024 & 2030
• Fig. 22 Oncology market, 2018 - 2030 (USD Million)
• Fig. 23 Autoimmune diseases market, 2018 - 2030 (USD Million)
• Fig. 24 Infectious diseases market, 2018 - 2030 (USD Million)
• Fig. 25 Cardiovascular diseases market, 2018 - 2030 (USD Million)
• Fig. 26 Metabolic diseases market, 2018 - 2030 (USD Million)
• Fig. 27 Neurology market, 2018 - 2030 (USD Million)
• Fig. 28 Others market, 2018 - 2030 (USD Million)
• Fig. 29 Biologics contract manufacturing market revenue, by region
• Fig. 30 Regional marketplace: Key takeaways
• Fig. 31 Regional marketplace: Key takeaways
• Fig. 32 North America biologics contract manufacturing market, 2018 - 2030 (USD Million)
• Fig. 33 U.S. country dynamics
• Fig. 34 U.S. biologics contract manufacturing market, 2018 - 2030 (USD Million)
• Fig. 35 Canada country dynamics
• Fig. 36 Canada biologics contract manufacturing market, 2018 - 2030 (USD Million)
• Fig. 37 Mexico country dynamics
• Fig. 38 Mexico biologics contract manufacturing market, 2018 - 2030 (USD Million)
• Fig. 39 Europe biologics contract manufacturing market, 2018 - 2030 (USD Million)
• Fig. 40 UK country dynamics
• Fig. 41 UK biologics contract manufacturing market, 2018 - 2030 (USD Million)
• Fig. 42 Germany country dynamics
• Fig. 43 Germany biologics contract manufacturing market, 2018 - 2030 (USD Million)
• Fig. 44 France country dynamics
• Fig. 45 France biologics contract manufacturing market, 2018 - 2030 (USD Million)
• Fig. 46 Italy country dynamics
• Fig. 47 Italy biologics contract manufacturing market, 2018 - 2030 (USD Million)
• Fig. 48 Spain country dynamics
• Fig. 49 Spain biologics contract manufacturing market, 2018 - 2030 (USD Million)
• Fig. 50 Denmark country dynamics
• Fig. 51 Denmark biologics contract manufacturing market, 2018 - 2030 (USD Million)
• Fig. 52 Sweden country dynamics
• Fig. 53 Sweden biologics contract manufacturing market, 2018 - 2030 (USD Million)
• Fig. 54 Norway country dynamics
• Fig. 55 Norway biologics contract manufacturing market, 2018 - 2030 (USD Million)
• Fig. 56 Asia Pacific biologics contract manufacturing market, 2018 - 2030 (USD Million)
• Fig. 57 Japan country dynamics
• Fig. 58 Japan biologics contract manufacturing market, 2018 - 2030 (USD Million)
• Fig. 59 China country dynamics
• Fig. 60 China biologics contract manufacturing market, 2018 - 2030 (USD Million)
• Fig. 61 India country dynamics
• Fig. 62 India biologics contract manufacturing market, 2018 - 2030 (USD Million)
• Fig. 63 Australia country dynamics
• Fig. 64 Australia biologics contract manufacturing market, 2018 - 2030 (USD Million)
• Fig. 65 Thailand country dynamics
• Fig. 66 Thailand biologics contract manufacturing market, 2018 - 2030 (USD Million)
• Fig. 67 South Korea country dynamics
• Fig. 68 South Korea biologics contract manufacturing market, 2018 - 2030 (USD Million)
• Fig. 69 Latin America biologics contract manufacturing market, 2018 - 2030 (USD Million)
• Fig. 70 Brazil country dynamics
• Fig. 71 Brazil biologics contract manufacturing market, 2018 - 2030 (USD Million)
• Fig. 72 Argentina country dynamics
• Fig. 73 Argentina biologics contract manufacturing market, 2018 - 2030 (USD Million)
• Fig. 74 MEA biologics contract manufacturing market, 2018 - 2030 (USD Million)
• Fig. 75 South Africa country dynamics
• Fig. 76 South Africa biologics contract manufacturing market, 2018 - 2030 (USD Million)
• Fig. 77 Saudi Arabia country dynamics
• Fig. 78 Saudi Arabia biologics contract manufacturing market, 2018 - 2030 (USD Million)
• Fig. 79 UAE country dynamics
• Fig. 80 UAE biologics contract manufacturing market, 2018 - 2030 (USD Million)
• Fig. 81 Kuwait country dynamics
• Fig. 82 Kuwait biologics contract manufacturing market, 2018 - 2030 (USD Million)
• Fig. 83 Company categorization
• Fig. 84 Company market position analysis
• Fig. 85 Strategic framework

Biologics Contract Manufacturing Market Growth & Trends:

The global biologics contract manufacturing market size is expected to reach USD 57.59 billion by 2030, registering a CAGR of 10.3% from 2025 to 2030, according to a new report by Grand View Research, Inc. The global market was growing efficiently during the COVID-19 pandemic. This is due to a rise in R&D activities for the development of COVID-19 vaccines. In addition, there has been an expansion in manufacturing facilities to control the spread of the disease. For instance, in November 2021, Lonza announced that it has decided to expand its microbial development laboratories in Switzerland to support the company's upcoming projects.

It is believed that post-pandemic there will be numerous fundamental changes. There will be an increase in the production and manufacturing efforts for the development of vaccines and therapeutics against the coronavirus and a rise in digital capabilities across all their operating units. These initiatives will help them in joint planning with pharma clients in building more strategic partnerships. For instance, in January 2022, Lonza launched a technology that will be used for the discovery and design of antibodies that are biospecific and this technology will be called bYlok(TM). The outsourcing of drugs or biologics manufacturing is rapidly increasing around the world.

Pharmaceutical and biotechnology companies concentrate on their core projects while reducing the operational costs associated with manufacturing drugs or biologics. Contract Manufacturing Organizations (CMOs) are specialized and experienced in conducting the entire process of manufacturing. In-house manufacturing of biologics is difficult as it is a complex process and involves many resources. CMOs link the demand and supply gap by focusing on improving the drug discovery process resulting in faster availability of biologics for patients. Hence, due to these factors, outsourcing activities are rapidly increasing.

Biologics Contract Manufacturing Market Report Highlights:

• Based on products, the MABs segment accounted for the largest revenue share in 2024 as MABs are used in the treatment of a wide range of diseases, such as cancer, infectious diseases, asthma, and auto-immune diseases
• Based on indications, the oncology segment dominated the market in 2024 with the largest revenue share. The main factor responsible for the high segment share is the increased number of cancer cases
• North America dominated the global market in 2024 due to the increased outsourcing services for manufacturing drugs & biologics and high R&D expenditure in the region

Table of Contents

Chapter 1. Methodology and Scope

• 1.1. Market Segmentation & Scope
• 1.2. Segment Definitions
  • 1.2.1. Product
  • 1.2.2. Indication
• 1.3. Estimates and Forecast Timeline
• 1.4. Research Methodology
• 1.5. Information Procurement
  • 1.5.1. Purchased Database
  • 1.5.2. GVR's Internal Database
  • 1.5.3. Secondary Sources
  • 1.5.4. Primary Research
• 1.6. Information Analysis
  • 1.6.1. Data Analysis Models
• 1.7. Market Formulation & Data Visualization
• 1.8. Model Details
  • 1.8.1. Commodity Flow Analysis
• 1.9. List of Secondary Sources
• 1.10. Objectives

Chapter 2. Executive Summary

• 2.1. Market Snapshot
• 2.2. Segment Snapshot
• 2.3. Competitive Landscape Snapshot

Chapter 3. Biologics Contract Manufacturing Market Variables, Trends, & Scope

• 3.1. Market Lineage Outlook
• 3.2. Market Dynamics
  • 3.2.1. Market Driver Analysis
  • 3.2.2. Market Restraint Analysis
• 3.3. Business Environment Analysis
  • 3.3.1. Industry Analysis - Porter's Five Forces Analysis
    • 3.3.1.1. Supplier Power
    • 3.3.1.2. Buyer Power
    • 3.3.1.3. Substitution Threat
    • 3.3.1.4. Threat of New Entrants
    • 3.3.1.5. Competitive Rivalry
  • 3.3.2. PESTLE Analysis

Chapter 4. Biologics Contract Manufacturing Market: Product Business Analysis

• 4.1. Product Market Share, 2024 & 2030
• 4.2. Product Segment Dashboard
• 4.3. Market Size & Forecasts and Trend Analysis, by Product, 2018 to 2030 (USD Million)
• 4.4. Monoclonal Antibodies (mAbs)
  • 4.4.1. Monoclonal Antibodies (mAbs) Market, 2018 - 2030 (USD Million)
• 4.5. Recombinant Proteins
  • 4.5.1. Recombinant Proteins Market, 2018 - 2030 (USD Million)
• 4.6. Vaccines
  • 4.6.1. Vaccines Market, 2018 - 2030 (USD Million)
• 4.7. Antisense, RNAi, & Molecular Therapy
  • 4.7.1. Antisense, RNAi, & Molecular Therapy Market, 2018 - 2030 (USD Million)
• 4.8. Others
  • 4.8.1. Others Market, 2018 - 2030 (USD Million)

Chapter 5. Biologics contract manufacturing Market: Indication Business Analysis

• 5.1. Indication Market Share, 2024 & 2030
• 5.2. Indication Segment Dashboard
• 5.3. Market Size & Forecasts and Trend Analysis, by Indication, 2018 to 2030 (USD Million)
• 5.4. Oncology
  • 5.4.1. Oncology Market, 2018 - 2030 (USD Million)
• 5.5. Autoimmune Diseases
  • 5.5.1. Autoimmune Diseases Market, 2018 - 2030 (USD Million)
• 5.6. Infectious Diseases
  • 5.6.1. Infectious Diseases Market, 2018 - 2030 (USD Million)
• 5.7. Cardiovascular Diseases
  • 5.7.1. Cardiovascular Diseases Market, 2018 - 2030 (USD Million)
• 5.8. Metabolic Diseases
  • 5.8.1. Metabolic Diseases Market, 2018 - 2030 (USD Million)
• 5.9. Neurology
  • 5.9.1. Neurology Market, 2018 - 2030 (USD Million)
• 5.10. Others
  • 5.10.1. Others Market, 2018 - 2030 (USD Million)

Chapter 6. Biologics Contract Manufacturing Market: Regional Estimates & Trend Analysis by Product and Indication

• 6.1. Regional Market Share Analysis, 2024 & 2030
• 6.2. Regional Market Dashboard
• 6.3. Market Size & Forecasts Trend Analysis, 2018 to 2030:
• 6.4. North America
  • 6.4.1. North America Biologics Contract Manufacturing Market Estimates And Forecasts, By Country, 2018 - 2030 (USD Million)
  • 6.4.2. U.S.
    • 6.4.2.1. Key Country Dynamics
    • 6.4.2.2. Regulatory Framework
    • 6.4.2.3. Competitive Insights
    • 6.4.2.4. U.S. Biologics Contract Manufacturing Market Estimates And Forecasts, 2018 - 2030 (USD Million)
  • 6.4.3. Canada
    • 6.4.3.1. Key Country Dynamics
    • 6.4.3.2. Regulatory Framework
    • 6.4.3.3. Competitive Insights
    • 6.4.3.4. Canada Biologics Contract Manufacturing Market Estimates And Forecasts, 2018 - 2030 (USD Million)
  • 6.4.4. Mexico
    • 6.4.4.1. Key Country Dynamics
    • 6.4.4.2. Regulatory Framework
    • 6.4.4.3. Competitive Insights
    • 6.4.4.4. Mexico Biologics Contract Manufacturing Market Estimates And Forecasts, 2018 - 2030 (USD Million)
• 6.5. Europe
  • 6.5.1. Europe Biologics Contract Manufacturing Market Estimates And Forecasts, By Country, 2018 - 2030 (USD Million)
  • 6.5.2. UK
    • 6.5.2.1. Key Country Dynamics
    • 6.5.2.2. Regulatory Framework
    • 6.5.2.3. Competitive Insights
    • 6.5.2.4. UK Biologics Contract Manufacturing Market Estimates And Forecasts, 2018 - 2030 (USD Million)
  • 6.5.3. Germany
    • 6.5.3.1. Key Country Dynamics
    • 6.5.3.2. Regulatory Framework
    • 6.5.3.3. Competitive Insights
    • 6.5.3.4. Germany Biologics Contract Manufacturing Market Estimates And Forecasts, 2018 - 2030 (USD Million)
  • 6.5.4. France
    • 6.5.4.1. Key Country Dynamics
    • 6.5.4.2. Regulatory Framework
    • 6.5.4.3. Competitive Insights
    • 6.5.4.4. France Biologics Contract Manufacturing Market Estimates And Forecasts, 2018 - 2030 (USD Million)
  • 6.5.5. Italy
    • 6.5.5.1. Key Country Dynamics
    • 6.5.5.2. Regulatory Framework
    • 6.5.5.3. Competitive Insights
    • 6.5.5.4. Italy Biologics Contract Manufacturing Market Estimates And Forecasts, 2018 - 2030 (USD Million)
  • 6.5.6. Spain
    • 6.5.6.1. Key Country Dynamics
    • 6.5.6.2. Regulatory Framework
    • 6.5.6.3. Competitive Insights
    • 6.5.6.4. Spain Biologics Contract Manufacturing Market Estimates And Forecasts, 2018 - 2030 (USD Million)
  • 6.5.7. Denmark
    • 6.5.7.1. Key Country Dynamics
    • 6.5.7.2. Regulatory Framework
    • 6.5.7.3. Competitive Insights
    • 6.5.7.4. Denmark Biologics Contract Manufacturing Market Estimates And Forecasts, 2018 - 2030 (USD Million)
  • 6.5.8. Sweden
    • 6.5.8.1. Key Country Dynamics
    • 6.5.8.2. Regulatory Framework
    • 6.5.8.3. Competitive Insights
    • 6.5.8.4. Sweden Biologics Contract Manufacturing Market Estimates And Forecasts, By Country, 2018 - 2030 (USD Million)
  • 6.5.9. Norway
    • 6.5.9.1. Key Country Dynamics
    • 6.5.9.2. Regulatory Framework
    • 6.5.9.3. Competitive Insights
    • 6.5.9.4. Norway Biologics Contract Manufacturing Market Estimates And Forecasts, 2018 - 2030 (USD Million)
• 6.6. Asia Pacific
  • 6.6.1. Asia Pacific Biologics Contract Manufacturing Market Estimates And Forecasts, 2018 - 2030 (USD Million)
  • 6.6.2. Japan
    • 6.6.2.1. Key Country Dynamics
    • 6.6.2.2. Regulatory Framework
    • 6.6.2.3. Competitive Insights
    • 6.6.2.4. Japan Biologics Contract Manufacturing Market Estimates And Forecasts, 2018 - 2030 (USD Million)
  • 6.6.3. China
    • 6.6.3.1. Key Country Dynamics
    • 6.6.3.2. Regulatory Framework
    • 6.6.3.3. Competitive Insights
    • 6.6.3.4. China Biologics Contract Manufacturing Market Estimates And Forecasts, 2018 - 2030 (USD Million)
  • 6.6.4. India
    • 6.6.4.1. Key Country Dynamics
    • 6.6.4.2. Regulatory Framework
    • 6.6.4.3. Competitive Insights
    • 6.6.4.4. India Biologics Contract Manufacturing Market Estimates And Forecasts, 2018 - 2030 (USD Million)
  • 6.6.5. Australia
    • 6.6.5.1. Key Country Dynamics
    • 6.6.5.2. Regulatory Framework
    • 6.6.5.3. Competitive Insights
    • 6.6.5.4. Australia Biologics Contract Manufacturing Market Estimates And Forecasts, 2018 - 2030 (USD Million)
  • 6.6.6. Thailand
    • 6.6.6.1. Key Country Dynamics
    • 6.6.6.2. Regulatory Framework
    • 6.6.6.3. Competitive Insights
    • 6.6.6.4. Thailand Biologics Contract Manufacturing Market Estimates And Forecasts, 2018 - 2030 (USD Million)
  • 6.6.7. South Korea
    • 6.6.7.1. Key Country Dynamics
    • 6.6.7.2. Regulatory Framework
    • 6.6.7.3. Competitive Insights
    • 6.6.7.4. South Korea Biologics Contract Manufacturing Market Estimates And Forecasts, 2018 - 2030 (USD Million)
• 6.7. Latin America
  • 6.7.1. Latin America Biologics Contract Manufacturing Market Estimates And Forecasts, By Country, 2018 - 2030 (USD Million)
  • 6.7.2. Brazil
    • 6.7.2.1. Key Country Dynamics
    • 6.7.2.2. Regulatory Framework
    • 6.7.2.3. Competitive Insights
    • 6.7.2.4. Brazil Biologics Contract Manufacturing Market Estimates And Forecasts, 2018 - 2030 (USD Million)
  • 6.7.3. Argentina
    • 6.7.3.1. Key Country Dynamics
    • 6.7.3.2. Regulatory Framework
    • 6.7.3.3. Competitive Insights
    • 6.7.3.4. Argentina Biologics Contract Manufacturing Market Estimates And Forecasts, 2018 - 2030 (USD Million)
• 6.8. MEA
  • 6.8.1. MEA Biologics Contract Manufacturing Market Estimates And Forecasts, By Country, 2018 - 2030 (USD Million)
  • 6.8.2. South Africa
    • 6.8.2.1. Key Country Dynamics
    • 6.8.2.2. Regulatory Framework
    • 6.8.2.3. Competitive Insights
    • 6.8.2.4. South Africa Biologics Contract Manufacturing Market Estimates And Forecasts, 2018 - 2030 (USD Million)
  • 6.8.3. Saudi Arabia
    • 6.8.3.1. Key Country Dynamics
    • 6.8.3.2. Regulatory Framework
    • 6.8.3.3. Competitive Insights
    • 6.8.3.4. Saudi Arabia Biologics Contract Manufacturing Market Estimates And Forecasts, 2018 - 2030 (USD Million)
  • 6.8.4. UAE
    • 6.8.4.1. Key Country Dynamics
    • 6.8.4.2. Regulatory Framework
    • 6.8.4.3. Competitive Insights
    • 6.8.4.4. UAE Biologics Contract Manufacturing Market Estimates And Forecasts, 2018 - 2030 (USD Million)
  • 6.8.5. Kuwait
    • 6.8.5.1. Key Country Dynamics
    • 6.8.5.2. Regulatory Framework
    • 6.8.5.3. Competitive Insights
    • 6.8.5.4. Kuwait Biologics Contract Manufacturing Market Estimates And Forecasts, 2018 - 2030 (USD Million)

Chapter 7. Competitive Landscape

• 7.1. Participant Overview
• 7.2. Company Market Position Analysis
• 7.3. Company Categorization
• 7.4. Strategy Mapping
• 7.5. Company Profiles/Listing
  • 7.5.1. Wuxi Biologics.
    • 7.5.1.1. Overview
    • 7.5.1.2. Financial Performance
    • 7.5.1.3. Product Benchmarking
    • 7.5.1.4. Strategic Initiatives
  • 7.5.2. FUJIFILM Diosynth Biotechnologies.
    • 7.5.2.1. Overview
    • 7.5.2.2. Financial Performance
    • 7.5.2.3. Product Benchmarking
    • 7.5.2.4. Strategic Initiatives
  • 7.5.3. Boehringer Ingelheim International GmbH
    • 7.5.3.1. Overview
    • 7.5.3.2. Financial Performance
    • 7.5.3.3. Product Benchmarking
    • 7.5.3.4. Strategic Initiatives
  • 7.5.4. Lonza
    • 7.5.4.1. Overview
    • 7.5.4.2. Financial Performance
    • 7.5.4.3. Product Benchmarking
    • 7.5.4.4. Strategic Initiatives
  • 7.5.5. Samsung Biologics
    • 7.5.5.1. Overview
    • 7.5.5.2. Financial Performance
    • 7.5.5.3. Product Benchmarking
    • 7.5.5.4. Strategic Initiatives
  • 7.5.6. AbbVie Inc.
    • 7.5.6.1. Overview
    • 7.5.6.2. Financial Performance
    • 7.5.6.3. Product Benchmarking
    • 7.5.6.4. Strategic Initiatives
  • 7.5.7. Catalent
    • 7.5.7.1. Overview
    • 7.5.7.2. Financial Performance
    • 7.5.7.3. Product Benchmarking
    • 7.5.7.4. Strategic Initiatives
  • 7.5.8. Bioreliance (Merck KGaA)
    • 7.5.8.1. Overview
    • 7.5.8.2. Financial Performance
    • 7.5.8.3. Product Benchmarking
    • 7.5.8.4. Strategic Initiatives
  • 7.5.9. Thermo Fisher Scientific Inc.
    • 7.5.9.1. Overview
    • 7.5.9.2. Financial Performance
    • 7.5.9.3. Product Benchmarking
    • 7.5.9.4. Strategic Initiatives
  • 7.5.10. Eurofins Scientific
    • 7.5.10.1. Overview
    • 7.5.10.2. Financial Performance
    • 7.5.10.3. Product Benchmarking
    • 7.5.10.4. Strategic Initiatives